Mayne Pharma (ASX:MYX) is an Australian-listed specialty pharmaceutical company focused on commercialising branded and generic pharmaceuticals. The company has a 40-year track record of innovation and success in developing new oral drug delivery systems, and it has a portfolio of over 100 commercialised products and a pipeline of over 50 products in development. Mayne Pharma's operations are focused on the commercialisation of its products in the United States and Australia, the two largest pharmaceutical markets in the world. The company also has a growing presence in other markets, such as Europe and Asia.